Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | DGKA | P23743 | 2/20 | 0.46 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.45 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.45 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30180550 | 1.00 | MGLL (0.51) | MGLLEPHX2DGKAPRKCEPRKCQ | |
| SCHEMBL28968652 | 1.00 | MGLL (0.51) | MGLLEPHX2DGKAPRKCEPRKCQ | |
| SCHEMBL747314 | 1.00 | MGLL (0.51) | MGLLEPHX2DGKAPRKCEPRKCQ | |
| Water SCHEMBL6549699 | 0.99 | MGLL (0.50) | MGLLEPHX2DGKAPRKCEPRKCQ | |
| Hydrochloric Acid SCHEMBL421821 | 0.99 | MGLL (0.50) | MGLLEPHX2DGKAPRKCEPRKCQ | |
| Hydrochloric Acid SCHEMBL1047267 | 0.99 | MGLL (0.50) | MGLLEPHX2DGKAPRKCEPRKCQ | |
| Hydrochloric Acid SCHEMBL29396916 | 0.99 | MGLL (0.50) | MGLLEPHX2DGKAPRKCEPRKCQ | |
| Hydrochloric Acid SCHEMBL28736736 | 0.98 | MGLL (0.49) | MGLLEPHX2DGKAPRKCEPRKCQ | |
| SCHEMBL1044584 | 0.93 | DGKA (0.50) | MGLLEPHX2DGKAPRKCEPRKCQ | |
| Hydrochloric Acid SCHEMBL18209372 | 0.92 | DGKA (0.49) | MGLLEPHX2DGKAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4312989-A1 | FORMULATION FOR MESSENGER RNA DELIVERY | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) | 2024-02-07 | — | — | EP | claimed |
| WO-2022207736-A1 | FORMULATION FOR MESSENGER RNA DELIVERY | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2022-10-06 | — | — | WO | claimed |
| EP-3328423-B1 | ENHANCED IMMUNE RESPONSE IN FISH | BAYER ANIMAL HEALTH GMBH (DE) | 2021-05-26 | — | — | EP | claimed |
| EP-3377114-B1 | IMMUNOGENIC COMPOSITION IN THE FORM OF AN EMULSION COMPRISING TWO DISPERSED PHASES, ONE COMPRISING AN ANTIGEN AND THE OTHER COMPRISING AN IMMUNOSTIMULATING AGENT | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2020-07-08 | — | — | EP | claimed |
| EP-2763657-B1 | MOLECULE MIXTURE COMPRISING AN AMPHIPATHIC MOLECULE TYPE A, WHICH HAS A POSITIVE TOTAL CHARGE IN THE HYDROPHILIC RANGE, AND AN AMPHIPATHIC MOLECULE TYPE B AND A POLYPHENOL C, METHOD FOR PRODUCING SAID MOLECULE MIXTURE AND USE THEREOF | FORSCHUNGSZENTRUM JUELICH GMBH (DE) | 2020-03-25 | — | — | EP | claimed |
| US-10597700-B2 | High-throughput screening method for the identification of biomarkers, therapeutic targets or therapeutic agents | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2020-03-24 | — | — | US | claimed |
| US-10253315-B2 | Method for transfection of nucleic acids into eukaryotic cells in 3D scaffold | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2019-04-09 | — | — | US | claimed |
| EP-3377114-A1 | IMMUNOGENIC COMPOSITION IN THE FORM OF AN EMULSION COMPRISING TWO DISPERSED PHASES, ONE COMPRISING AN ANTIGEN AND THE OTHER COMPRISING AN IMMUNOSTIMULATING AGENT | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2018-09-26 | — | — | EP | claimed |
| EP-2890364-B1 | FORMULATION FOR THE DELIVERY OF NUCLEOTIDE SEQUENCES THAT CAN MODULATE ENDOGENOUS INTERFERING RNA MECHANISMS | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2018-01-10 | — | — | EP | claimed |
| EP-2961423-B1 | IMMUNOGENIC COMPOSITION IN EMULSION FORM | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2017-07-26 | — | — | EP | claimed |
| US-20150258022-A1 | Formulation for the Delivery of Nucleotide Sequences That Can Modulate Endogenous Interfering RNA Mechanisms | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-09-17 | — | — | US | claimed |
| EP-2890364-A1 | FORMULATION FOR THE DELIVERY OF NUCLEOTIDE SEQUENCES THAT CAN MODULATE ENDOGENOUS INTERFERING RNA MECHANISMS | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2015-07-08 | — | — | EP | claimed |
| WO-2014131809-A1 | IMMUNOGENIC COMPOSITION IN EMULSION FORM | Commissariat à l'énergie atomique et aux énergies alternatives (FR) | 2014-09-04 | — | — | WO | claimed |
| WO-2014083205-A1 | HIGH-THROUGHPUT SCREENING METHOD FOR THE IDENTIFICATION OF BIOMARKERS, THERAPEUTIC TARGETS OR THERAPEUTIC AGENTS | Commissariat à l'énergie atomique et aux énergies alternatives (FR) | 2014-06-05 | — | — | WO | claimed |
| WO-2014032953-A1 | FORMULATION FOR THE DELIVERY OF NUCLEOTIDE SEQUENCES THAT CAN MODULATE ENDOGENOUS INTERFERING RNA MECHANISMS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2014-03-06 | — | — | WO | claimed |
| EP-1648379-A4 | VACCINES USING PATTERN RECOGNITION RECEPTOR-LIGAND:LIPID COMPLEXES | JUVARIS BIOTHERAPEUTICS INC (US) | 2008-01-16 | — | — | EP | claimed |
| EP-1648379-A2 | VACCINES USING PATTERN RECOGNITION RECEPTOR-LIGAND:LIPID COMPLEXES | Juvaris Biotherapeutics, Inc. (US) | 2006-04-26 | — | — | EP | claimed |
| WO-2005013891-A2 | VACCINES USING PATTERN RECOGNITION RECEPTOR-LIGAND:LIPID COMPLEXES | JUVARIS BIOTHERAPEUTICS, INC. (US) | 2005-02-17 | — | — | WO | claimed |
| US-20050013812-A1 | Vaccines using pattern recognition receptor-ligand:lipid complexes | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-01-20 | — | — | US | claimed |
| EP-0832270-B1 | CATIONIC LIPID:DNA COMPLEXES FOR GENE TARGETING | VALENTIS INC (US) | 2004-10-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150258022-A1 | Formulation for the Delivery of Nucleotide Sequences That Can Modulate Endogenous Interfering RNA Mechanisms | NSUN2, RNMT, SNRPA | MGLL 2546/4885EPHX2 4171/4885DGKA 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.